Lilly’s pair of deals includes rights to MeiraGTx’s vision-restoring gene therapy: Deals Report

Monday morning delivered a handful of deals, with Lilly entering a pair of agreements: in-licensing a gene therapy, and striking another deal to use artificial intelligence in drug design.

Eli Lilly and Co. (NYSE:LLY) will pay MeiraGTx Holdings plc (NASDAQ:MGTX) $75 million up front to gain exclusive, worldwide rights to a gene therapy for AIPL1-associated Leber congenital amaurosis 4 (LCA4). The therapy is one of four programs MeiraGTx has advanced to pivotal testing. Based on results of a U.K. study in which all 11 children receiving the therapy have shown benefits in visual acuity, MeiraGTx has been preparing regulatory submissions in the U.S. and U.K...